Status:

COMPLETED

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Lead Sponsor:

Yonsei University

Conditions:

Diabetic Retinopathy

Eligibility:

All Genders

Phase:

NA

Brief Summary

Recently, intravitreal bevacizumab (Avastin) injection has gained popularity as a potential treatment of intraocular neovascularization (CNV) associated with age related macular degeneration and diabe...

Eligibility Criteria

Inclusion

  • Tractional retinal detachment recently involving the macula with fibrovascular membrane due to proliferative diabetic retinopathy
  • Severe fibrovascular proliferation progressing after appropriate panretinal photocoagulation

Exclusion

  • Uncontrolled systemic hypertension
  • Recent history of myocardiac infarction within 6 months
  • Recent history of cerebrovascular accident within 6 months

Key Trial Info

Start Date :

December 1 2006

Trial Type :

INTERVENTIONAL

End Date :

March 1 2007

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00423059

Start Date

December 1 2006

End Date

March 1 2007

Last Update

March 13 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Ophthalmology, Yonsei University College of Medicine

Seoul, South Korea, 120-752